Lymphoplasmacytic lymphoma risk factors

Jump to navigation Jump to search

Lymphoplasmacytic lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Lymphoplasmacytic Lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lymphoplasmacytic lymphoma risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lymphoplasmacytic lymphoma risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lymphoplasmacytic lymphoma risk factors

CDC on Lymphoplasmacytic lymphoma risk factors

Lymphoplasmacytic lymphoma risk factors in the news

Blogs on Lymphoplasmacytic lymphoma risk factors

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Lymphoplasmacytic lymphoma risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]

Overview

Common risk factors in the development of lymphoplasmacytic lymphoma are monoclonal gammopathy of undetermined significance, heredity, hepatitis C and other autoimmune disorders, allergic conditions like hay fever and multiple environmental factors such as occupational (farming), pesticides, paint, rubber dyes,benzene, coal dust, leather manufacturing, wood dust, and organic solvents.

Risk Factors

Common risk factors in the development of lymphoplasmacytic lymphoma include:[1]

References

  1. Waldenström's macroglobulinemia. American Cancer Society (2015)http://www.cancer.org/cancer/waldenstrommacroglobulinemia/detailedguide/waldenstrom-macroglobulinemia-risk-factors Accessed on November 6, 2015
  2. Treon SP, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C; et al. (2006). "Characterization of familial Waldenstrom's macroglobulinemia". Ann Oncol. 17 (3): 488–94. doi:10.1093/annonc/mdj111. PMID 16357024.
  3. McMaster ML, Csako G, Giambarresi TR, Vasquez L, Berg M, Saddlemire S; et al. (2007). "Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families". Clin Cancer Res. 13 (17): 5063–9. doi:10.1158/1078-0432.CCR-07-0299. PMID 17785558.
  4. 4.0 4.1 Kristinsson SY, Björkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O (2008). "Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden". Blood. 112 (8): 3052–6. doi:10.1182/blood-2008-06-162768. PMC 2569164. PMID 18703425.
  5. 5.0 5.1 5.2 Koshiol J, Gridley G, Engels EA, McMaster ML, Landgren O (2008). "Chronic immune stimulation and subsequent Waldenström macroglobulinemia". Arch Intern Med. 168 (17): 1903–9. doi:10.1001/archinternmed.2008.4. PMC 2670401. PMID 18809818.
  6. de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM; et al. (2008). "Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium". Clin Gastroenterol Hepatol. 6 (4): 451–8. doi:10.1016/j.cgh.2008.02.011. PMC 3962672. PMID 18387498.
  7. 7.0 7.1 Kristinsson SY, Koshiol J, Björkholm M, Goldin LR, McMaster ML, Turesson I; et al. (2010). "Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia". J Natl Cancer Inst. 102 (8): 557–67. doi:10.1093/jnci/djq043. PMC 2857799. PMID 20181958.
  8. 8.0 8.1 8.2 Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J; et al. (2008). "Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium". Blood. 111 (8): 4029–38. doi:10.1182/blood-2007-10-119974. PMC 2288717. PMID 18263783.
  9. Landgren O, Engels EA, Pfeiffer RM, Gridley G, Mellemkjaer L, Olsen JH; et al. (2006). "Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia". J Natl Cancer Inst. 98 (18): 1321–30. doi:10.1093/jnci/djj361. PMID 16985251.
  10. Royer RH, Koshiol J, Giambarresi TR, Vasquez LG, Pfeiffer RM, McMaster ML (2010). "Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation". Blood. 115 (22): 4464–71. doi:10.1182/blood-2009-10-247973. PMC 2881498. PMID 20308603.
  11. Vajdic CM, Landgren O, McMaster ML, Slager SL, Brooks-Wilson A, Smith A; et al. (2014). "Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project". J Natl Cancer Inst Monogr. 2014 (48): 87–97. doi:10.1093/jncimonographs/lgu002. PMC 4155457. PMID 25174029.

Template:WH Template:WS